

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



LUYE PHARMA GROUP LTD.

绿叶制药集团有限公司

(Incorporated in Bermuda with limited liability)

(Stock Code: 02186)

ANNOUNCEMENT

INCLUSION OF LIPUSU[®] IN THE NEW CATALOGUE OF NATIONAL REIMBURSEMENT DRUG LIST

The board of directors (the “Board”) of Luye Pharma Group Ltd. (the “Company”, together with its subsidiaries, the “Group”) announce that, Lipusu[®], being the Group’s paclitaxel formulation with innovative liposome delivery system, has been included in the category B of the new Catalogue of National Reimbursement Drug List (“NRDL”). All indication of Lipusu[®], including non-small cell lungs Cancer, ovarian and breast cancer have all been reimbursed by the NDRL.

Lipusu[®] is the Group’s patented paclitaxel formulation with an innovative liposome delivery system and it is a chemotherapy indicated for various cancers such as non-small cell lung cancer, ovarian cancer and breast cancer. The Group holds a patent over the composition and formulation method of paclitaxel liposome in China. Lipusu[®] is the first paclitaxel liposome product approved for sale in the world and the only paclitaxel liposome product approved for sale in China as at the date of this announcement. According to IQVIA, Lipusu[®] was the second largest domestic pharmaceutical product for cancer treatment in China in the first half of 2020, as well as the most popular paclitaxel product in China in the first half of 2020.

Previously, paclitaxel liposome has been included in the 2020 Chinese Society of Clinical Oncology (“CSCO”) Guidelines on Diagnosis and Treatment of Breast Cancer, 2019 CSCO Guidelines on Diagnosis and Treatment of Primary Lung Cancer as a first-line drug, and has been included in the Expert Consensus on Clinical Application of Paclitaxel Drugs in Gynecological Malignancies and the 2020 Expert Consensus on Clinical Application of Paclitaxel Drugs in Breast Cancer. In addition, paclitaxel liposome in combination with other drugs have also been recommended as the preferred options for multiple radiotherapy and chemotherapy by the 2019 Guidelines on Radiotherapy of Esophageal Cancer.

The Board believes that, the inclusion of Lipusu[®] in the NRDL demonstrates that the National Healthcare Security Administration (“NHSA”) recognizes, among other factors, the clinical value, patients benefit and novelty of Lipusu[®]. This will also allow more patients to be able to afford Lipusu[®] increase its penetration into the relevant indications, and provide momentum to its long-term growth.

By Order of the Board
LUYE PHARMA GROUP LTD.
Liu Dian Bo
Chairman

Hong Kong, 28 December 2020

As at the date of this announcement, the executive directors of the Company are Mr. LIU Dian Bo, Mr. YANG Rong Bing, Mr. YUAN Hui Xian and Ms. ZHU Yuan Yuan; the non-executive Director of the Company is Mr. SONG Rui Lin; and the independent non-executive directors of the Company are Mr. ZHANG Hua Qiao, Professor LO Yuk Lam, Mr. LEUNG Man Kit and Mr. CHOY Sze Chung Jojo.